Interferon Gamma

SystImmune to Present Promising Data on Iza-bren for HER2-Negative Breast Cancer at ESMO Breast 2025

13 days ago

• SystImmune will present updated safety and efficacy data for izalontamab brengitecan (iza-bren), an EGFRxHER3 bispecific antibody-drug conjugate, in locally advanced or metastatic breast cancer at ESMO Breast 2025 on May 16. • Early clinical results show encouraging efficacy across all HER2 levels in HER2-negative breast cancer patients, including HER2 0 patients, suggesting potential therapeutic benefits for patients with limited treatment options. • Iza-bren, being jointly developed by SystImmune and Bristol Myers Squibb, works by blocking EGFR and HER3 signals to cancer cells while delivering a therapeutic payload that induces cancer cell death.

Sobi Launches Phase 2a Trial of Gamifant for Interferon-Gamma-Driven Sepsis

2 months ago

• Sobi has initiated the EMBRACE Phase 2a clinical trial to evaluate Gamifant (emapalumab) for treating interferon-gamma-driven sepsis (IDS), a newly identified endotype affecting approximately 20% of sepsis patients with 40-43% mortality rate. • The double-blind, randomized controlled trial will enroll 75 patients across 24 sites in Greece, targeting patients with the IDS endotype who do not exhibit sepsis-induced immunoparalysis. • The study represents a precision medicine approach to sepsis treatment, with primary endpoints measuring improvement in organ function and secondary endpoints including 28-day mortality and changes in inflammatory biomarkers.

Thykamine™ Shows Promising Anti-Fibrotic Effects Through Significant Gene Expression Changes in Preclinical Study

3 months ago

• Devonian Health Group's Thykamine™ demonstrated significant downregulation of key fibrosis-related genes in a preclinical mouse study, with inhibition rates reaching up to 77% for certain markers. • The oral treatment, tested at three different doses over three weeks, showed broad impact across multiple fibrosis-associated genes, suggesting potential applications in various organ-specific fibrotic conditions. • Results indicate Thykamine™ could expand beyond its anti-inflammatory properties to target fibrotic diseases across multiple organs, with statistically significant changes observed in critical markers like TGFβ, CCL2, and TIMP1.

Sonnet BioTherapeutics Advances SON-1010 Combination Trial for Sarcoma Treatment

4 months ago

• Sonnet BioTherapeutics expands Phase 1 SB101 trial to evaluate SON-1010 in combination with trabectedin for patients with unresectable, metastatic liposarcoma or leiomyosarcoma. • The trial will enroll up to 18 patients, with a primary focus on safety, tolerability, and pharmacokinetics, utilizing the established maximum tolerated dose of 1200 ng/kg. • SON-1010, a proprietary IL-12 formulation, aims to enhance immune response in the tumor microenvironment by converting 'cold' tumors to 'hot,' potentially improving treatment outcomes in earlier-stage patients.

IMUNON's IMNN-001 Receives FDA Agreement on Manufacturing for Phase 3 Ovarian Cancer Trial

7 months ago

• IMUNON has secured FDA alignment on its Chemistry, Manufacturing, and Controls (CMC) strategy for IMNN-001, an immunotherapy targeting advanced ovarian cancer. • The FDA has accepted IMUNON's potency assay for measuring interferon-gamma (IFN-γ) levels, crucial for both Phase 3 trials and potential commercial use. • IMUNON's in-house manufacturing facility in Huntsville, Alabama, will produce IMNN-001, ensuring cost-efficient production and quality control. • The company remains on track to initiate the 500-patient Phase 3 pivotal trial of IMNN-001 in the first quarter of 2025.